{"nct_id":"NCT01317875","title":"Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)","status":"COMPLETED","status_verified_date":"2025-08","start_date":"2011-03-31","start_date_type":"ACTUAL","primary_completion_date":"2019-12-31","primary_completion_date_type":"ACTUAL","completion_date":"2019-12-31","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["INCY"]}